Wells Fargo & Company Aptevo Therapeutics Inc. Transaction History

Wells Fargo & Company

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.17 - $0.38 $9 - $20	55 Added 3.52%	1,617 $0
Q3 2023 Nov 13, 2023	BUY	$0.31 - $1.78 $9 - $55	31 Added 2.02%	1,562 $0
Q2 2023 Aug 15, 2023	SELL	$1.34 - $2.08 $111 - $172	-83 Reduced 5.14%	1,531 $2,000
Q1 2023 May 12, 2023	BUY	$1.74 - $2.54 $1 - $2	1 Added 0.06%	1,614 $3,000
Q4 2022 Feb 13, 2023	SELL	$2.0 - $138.16 $282 - $19,480	-141 Reduced 8.04%	1,613 $3,000
Q3 2022 Nov 14, 2022	BUY	$3.12 - $142.56 $608 - $27,799	195 Added 12.51%	1,754 $5,000
Q2 2022 Aug 12, 2022	BUY	$3.26 - $6.3 $13 - $25	4 Added 0.26%	1,559 $5,000
Q4 2021 Feb 14, 2022	BUY	$6.48 - $17.49 $19 - $52	3 Added 0.19%	1,555 $12,000
Q3 2021 Nov 15, 2021	SELL	$15.01 - $22.16 $30 - $44	-2 Reduced 0.13%	1,552 $24,000
Q2 2021 Aug 16, 2021	BUY	$21.85 - $30.0 $21 - $30	1 Added 0.06%	1,554 $35,000
Q1 2021 May 13, 2021	BUY	$27.86 - $40.59 $27 - $40	1 Added 0.06%	1,553 $47,000
Q4 2020 Feb 09, 2021	BUY	$6.21 - $48.36 $6,812 - $53,050	1,097 Added 241.1%	1,552 $57,000
Q3 2020 Nov 05, 2020	BUY	$7.21 - $9.37 $36 - $46	5 Added 1.11%	455 $3,000
Q2 2020 Aug 13, 2020	BUY	$3.11 - $9.27 $1,321 - $3,939	425 Added 1700.0%	450 $4,000
Q1 2020 May 14, 2020	BUY	$3.29 - $9.73 $82 - $243	25 New	25 $0

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.5M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.